Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PPM1D | O15297 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878552 | 0.88 | HIF1A (0.54) | HIF1AHDAC8SENP1LOXL2FFAR1 | |
| SCHEMBL14420824 | 0.83 | LOXL2 (0.58) | HIF1ASENP1LOXL2SLC7A5PPM1D | |
| SCHEMBL5179550 | 0.82 | HIF1A (0.68) | HIF1AHDAC8SENP1FFAR1 | |
| SCHEMBL23286785 | 0.82 | CA1 (0.61) | HIF1AHDAC8LOXL2LNPEP | |
| SCHEMBL12139195 | 0.82 | HDAC8 (0.52) | HDAC8FFAR1 | |
| SCHEMBL1180032 | 0.79 | LOXL2 (0.53) | HIF1AHDAC8SENP1LOXL2SLC7A5 | |
| SCHEMBL521860 | 0.76 | AKR1C3 (0.68) | HDAC8 | |
| SCHEMBL8012083 | 0.76 | HDAC8 (0.50) | HDAC8FFAR1 | |
| SCHEMBL14165742 | 0.76 | BTK (0.53) | HIF1A | |
| SCHEMBL15761753 | 0.75 | HIF1A (0.85) | HIF1AHDAC8SENP1LOXL2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| WO-2009092566-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | PSEN1, AADAT, PSEN2 | HIF1A 2881/4885HDAC8 925/4885SENP1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.